Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Phase 3 failure

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

- PMLiVE

Takeda appoints GSK’s Weber as chief operating officer

Could take on CEO role next year

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

- PMLiVE

Takeda appoints new financial head

François-Xavier Roger brings experience from Sanofi and in telecoms

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

Takeda expands Latin American footprint

Opens new subsidiary in Peru

- PMLiVE

Phase III data raise hopes for Takeda’s vedolizumab

Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links